叶平

• 1:解放军总医院心内科

摘要(Abstract)：

<正>他汀类调脂药物的面世对于动脉粥样硬化性血管疾病的预防与治疗有着革命性的意义。在过去的十几年中,他汀类药物显著减少了各类人群的心血管事件。然而,不可忽视的是,大量研究证实,尽管他汀治疗后低密度脂蛋白胆固醇(LDL-C)浓度已经达标,但冠心病患者5年的主要血管事件发病率仍然高于20%[1]。1致动脉粥样硬化性血脂异常与心血管剩留风险心血管剩留风险:经过以目前临床证据为指导的标准治疗后(包括治疗确立的危险因素如不健康的生活方式、高胆固醇血症、高血压、高血糖、肥

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 叶平

参考文献(References)：

• [1]Cholesterol Treatment Trialists’(CTT)Collaboration,Baigent C,Blackwell L,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from170 000 participants in 26 randomised trials[J].Lancet,2010,376(9753):1670-1681.
• [2]中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.血脂相关性心血管剩留风险控制的中国专家共识[J].中华心血管病杂志,2012,40(7):547-553.
• [3]Miller M,Cannon CP,Murphy SA,et al.Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial[J].J Am Coll Cardiol,2008,51(7):724-730.
• [4]Pedersen TR,Faergeman O,Kastelein JJ,et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial[J].JAMA,2005,294(19):2437-2445.
• [5]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352(14):1425-1435.
• [6]Preiss D,Seshasai SR,Welsh P,et al.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis[J].JAMA,2011,305(24):2556-2564.
• [7]F ger B,Ritsch A,Doblinger A,et al.Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol.Studies in normotriglyceridemia and moderate hypertriglyceridemia[J].Art Thromb Vasc Biol,1996,16(12):1430-1436.
• [8]Sarwar N,Danesh J,Eiriksdottir G,et al.Triglycerides and the risk of coronary heart disease:10 158 incident cases among262 525 participants in 29 Western prospective studies[J].Circulation,2007,115(4):450-458.
• [9]Patel A,Barzi F,Jamrozik K,et al.Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region[J].Circulation,2004,110(17):2678-2686.
• [10]Carey VJ,Bishop L,Laranjo N,et al.Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control[J].Am J Cardiol,2010,106(6):757-763.
• [11]Lamarche B,Tchernof A,Moorjani S,et al.Small,dense lowdensity lipoprotein particles as a predictor of the risk of ischemic heart disease in men.Prospective results from the Québec Cardiovascular Study[J].Circulation,1997,95(1):69-75.
• [12]Chapman MJ,Redfern JS,McGovern ME,et al.Niacin and fibrates in atherogenic dyslipidemia:pharmacotherapy to reduce cardiovascular risk[J].Pharmacol Ther,2010,126(3):314-345.
• [13]Frick MH,Elo O,Haapa K,et al.Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.Safety of treatment,changes in risk factors,and incidence of coronary heart disease[J].N Engl J Med,1987,317(20):1237-1245.
• [14]Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group[J].N Engl J Med,1999,341(6):410-418.
• [15]The BIP Study Group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention(BIP)study[J].Circulation,2000,102(1):21-27.
• [16]Keech A,Simes RJ,Barter P,et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study):randomised controlled trial[J].Lancet,2005,366(9500):1849-1861.
• [17]Lee M,Saver JL,Towfighi A,et al.Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia:a meta-analysis[J].Atherosclerosis,2011,217(2):492-498.
• [18]Grundy SM,Vega GL,Yuan Z,et al.Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia(the SAFARI trial)[J].Am J Cardiol,2005,95(4):462-468.
• [19]Farnier M,Roth E,Gil-Extremera B,et al.Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia[J].Am Heart J,2007,153(2):335.e1-e8.
• [20]ACCORD Study Group,Ginsberg HN,Elam MB,et al.Effects of combination lipid therapy in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1563-1574.
• [21]Te n e n b a u m A,M e d v e d o f s k y D,F i s m a n E Z,e t a l.Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy:Acute Coronary Syndrome Israeli Surveys data[J].PLoS One,2012,7(4):e35298.
• [22]Geng Q,Ren J,Chen H,et al.Adverse events following statinfenofibrate therapy versus statin alone:a meta-analysis of randomized controlled trials[J].Clin Exp Pharmacol Physiol,2013,40(3):219-226.
• [23]AIM-HIGH Investigators,Boden WE,Probstfield JL,et al.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J].N Engl J Med,2011,365(24):2255-2267.
• [24]HPS2-THRIVE Collaborative Group.HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant:trial design,pre-specified muscle and liver outcomes,and reasons for stopping study treatment[J].Eur Heart J,2013,34(17):1279-1291.
• [25]Barter PJ,Caulfield M,Eriksson M,et al.Effects of torcetrapib in patients at high risk for coronary events[J].N Engl J Med,2007,357(21):2109-2122.
• [26]Schwartz GG,Olsson AG,Abt M,et al.Effects of dalcetrapib in patients with a recent acute coronary syndrome[J].N Engl J Med,2012,367(22):2089-2099.
• [27]Harris WS,Miller M,Tighe AP,et al.Omega-3 fatty acids and coronary heart disease risk:clinical and mechanistic perspectives[J].Atherosclerosis,2008,197(1):12-24.
• [28]Marchioli R,Barzi F,Bomba E,et al.Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction:time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico(GISSI)-Prevenzione[J].Circulation,2002,105(16):1897-1903.
• [29]Risk and Prevention Study Collaborative Group,Roncaglioni MC,Tombesi M,et al.n-3 fatty acids in patients with multiple cardiovascular risk factors[J].N Engl J Med,2013,368(19):1800-1808.